ReviewPharmacotherapy2007
Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome.
Review in Pharmacotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Meta-Analysis of Preclinical Studies of Fibrinolytic Therapy for Acute Lung Injury.Frontiers in immunology · 2018Pooled it
- Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID).Thrombosis research · 2020Trial
- Alterations in the human lung proteome with lipopolysaccharide.BMC pulmonary medicine · 2009Trial
- Scheduled Bronchoscopy with Nebulized Heparin and N-Acetylcysteine in Burn Patients with Inhalation Injury: A Randomized Trial.European burn journal · 2026Article
- KLF4 Protects Against Sepsis-Induced Coagulopathy via Inhibition of the AKT/mTOR/STAT3 Signaling Pathway.Journal of inflammation research · 2026Article
- Coagulation Disorders in Patients With Acute Respiratory Distress Syndrome Following Acute Aortic Dissection: A Prospective Observational Study.Reviews in cardiovascular medicine · 2025Article
- Acute lung injury caused by sepsis: how does it happen?Frontiers in medicine · 2023Review
- Article
- Nebulized Non-Immunogenic Staphylokinase in the Mice Acute Lung Injury Model.International journal of molecular sciences · 2022Article
- Immuno-Thrombotic Complications of COVID-19: Implications for Timing of Surgery and Anticoagulation.Frontiers in surgery · 2022Review
- Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management.Pneumonia (Nathan Qld.) · 2021Review
- Acute Respiratory Distress Syndrome: Focus on Viral Origin and Role of Pulmonary Lymphatics.Biomedicines · 2021Review
- Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications.Journal of the American College of Surgeons · 2021Review
- Thrombosis and Haemostasis challenges in COVID-19 - Therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions-a mini review.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2021Review
- Serratiopeptidase, A Serine Protease Anti-Inflammatory, Fibrinolytic, and Mucolytic Drug, Can Be a Useful Adjuvant for Management in COVID-19.Frontiers in pharmacology · 2021Article
- Molecular Mechanisms of Vascular Damage During Lung Injury.Advances in experimental medicine and biology · 2021Review
- Application of Critical Care Ultrasound in Patients With COVID-19: Our Experience and Perspective.IEEE transactions on ultrasonics, ferroelectrics, and frequency control · 2020Article
- Thromboelastography to Detect Hypercoagulability and Reduced Fibrinolysis in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome Patients.Critical care explorations · 2020Article
- Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Article
- Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.Journal of thrombosis and haemostasis : JTH · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are associated with high mortality rates despite therapeutic advances. The pathogenesis of ALI and ARDS is similar to that of sepsis, as these disease states involve uncontrolled host defense responses that lead to inflammation, endothelial damage, enhanced coagulation, diminished fibrinolysis, and fibroproliferation. Recent studies of anticoagulants have shown positive outcomes in patients with severe sepsis. In addition, emerging evidence suggests that the use of anticoagulants, such as tissue factor pathway inhibitor, antithrombin, thrombomodulin, heparin, activated protein C, and fibrinolytics (plasminogen activators and particularly tissue plasminogen activator), may be useful in the treatment of ALI and ARDS. Data from experimental models of sepsis, ALI, and ARDS indicate that some of these agents improve lung function and oxygenation. Although clinical data are less convincing than these findings, results from clinical trials may influence the design of future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.